Serum β-amyloid correlates with neuropsychological impairment

Aging, Neuropsychology, and Cognition

Volumn 16, Issue 2, 2009, Pages 203-218

  Luis, Cheryl A ^a,b   Abdullah, Laila ^a   Paris, Daniel ^a   Quadros, Amita ^a   Mullan, Myles ^a   Mouzon, Benoit ^a   Ait Ghezala, Ghania ^a   Crawford, Fiona ^a   Mullan, Michael ^a  

^a ROSKAMP INSTITUTE   (United States)

^b ABPP   (United States)

Author keywords

Alzheimer's disease; Biomarker; Cognition; Mild cognitive impairment; Neuropsychological impairment; Peripheral amyloid

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; LANGUAGE; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; SCORING SYSTEM; VELOCITY; ANALYSIS OF VARIANCE; BLOOD; COGNITIVE DEFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; MEMORY DISORDER; NEUROPSYCHOLOGICAL TEST; REGRESSION ANALYSIS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LANGUAGE; MALE; MEMORY DISORDERS; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; REGRESSION ANALYSIS;

EID: 63049110419     PISSN: 13825585     EISSN: 17444128     Source Type: Journal    
DOI: 10.1080/13825580802411766     Document Type: Article

References (37)

1. Abdullah, L., Paris, D., Luis, C, et al. (2007). The influence of diagnosis, intra- and inter- person variability on Serum and Plasma Aß levels. Neuroscience Letters, 428, 53-58. (Pubitemid 350051180)
2. Andersson, C, Blennow, K., Johansson, S., Almkvist, 0., Engfeldt, P., Lindau, M., & Eriksdotter-Jonhagen, M. (2007). Differential CSF biomarker levels in APOE episilon 4 positive and negative patients with memory impairments. Dementia & Geriatric Cogni- tive Disorders, 23, 87-95.
3. Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winbald, B., et al. (2001). Evaluation of CSF-tau and CSF Aßl2 as diagnostic markers for AD in clinical practice. Archives of Neurology, 58, 373-379. (Pubitemid 32217453)
4. Assini, A., Cammarata, A., Vitali, M., Colucci, L., Gilberto, R., Borghi, M., et al. (2004). Plasma levels of amyloid ß-protein 42 are increased in women with mild cognitive impair- ment. Neurology, 63, 828-831. (Pubitemid 39297642)
5. Bell, R., Sagare, A., Friedman, A., Bedi, G., Holtzman, D., Deane, R., et al. (2007). Transport pathways for clearance of human Alzheimer's amyloid beta-peptide an APOE E and J in the mouse central nervous system Journal of Cerebral Blood Flow and Metabolism, 27,909-918.
6. Blasko, L, Jellinger, K., Kemmler, G., et al. (2008). Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy, and homocysteine. Neurobiology of Aging, 29, 1-11. Braak, H., Braak, E., & Bohl, J. (1993). Staging of Alzheimer's related cortical destruction. European Neurology, 33, 403-408.
7. Casoli, T., Di Stefano, G., Giorgetti, B., et al. (2007). Release of beta-amyloid from high- density platelets: Implications for Alzheimer's disease pathology. Annals of the New York Academy of Sciences, 1096, 170-178. (Pubitemid 47092510)
8. Crowell, T., Luis, C, Vanderploeg, R., Schinka, J., & Mullan, M. (2003). Memory patterns and executive functioning in mild cognitive impairment and Alzheimer's disease. Aging, Neuropsychology, and Cognition, 9, 288-297.
9. Deane, R., Du Yan, S., Submamaryan, R., et al. (2003). RAGE mediates amyloid-beta peptides transport across the blood-brain barrier and accumulation in the brain. Natural Medicine, 9, 907-913. (Pubitemid 36889934)
10. Deane, R., Wu, Z., Sagare, A., et al. (2004). LPR/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron, 43, 333-344. (Pubitemid 39061126)
11. Ertekin-Taner, N., Younkin, L., Yager, D., et al. (2003). Plasma amyloid (beta) protein is elevated in late-onset Alzheimer's disease families. Neurology (epub ahead of print).
12. Freeman, S., Raju, S., Hyman, B., et al. (2007). Plasma Aß levels do not reflect brain Aß levels. Journal of Neuropathology and Experimental Neurology, 23, 264-271. (Pubitemid 46559019)
13. Fukomoto, H., Tennis, M., Locasci, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. (2003). Age but not diagnosis is the main predictor of plasma amyloid ß-protein levels. Archives of Neurology, 60, 958-964. (Pubitemid 36858355)
14. Giedraitis, V., Sundelof, J., Irizarry, M., et al. (2007). The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in AD. Neuroscience Letters, 427(3), 127-131. (Pubitemid 47633799)
15. Graff-Radford, N., Crook, J., Lucas, J., Boeve, B., Knopman, D., Ivnik, R., et al. (2007).
16. Association of low plasma Aß l-42/Aß 1-40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer's disease. Archives of Neurology, 64, 354-362.
17. Grober, E., Hall, C, Lipton, R. B., Zonderman, A. B., Resnick, S. M., & Kawas, C. (in press). Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. JINS.
18. Hampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., et al. (2004). Value of CSF beta-amyloid (1-1-42) and tau as predictors of AD in patients with mild cognitive impairment. Molecular Psychiatry, 9, 705-710.
19. Kawarabayashi, T., Younkin, L., Saido, T., Shoji, M., Ashe, K., & Younkin, S. (2001). Age- dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of AD. Journal of Neuroscience, 21, 372-381. (Pubitemid 32107428)
20. Kou, Y., Crawford, F., Mullan, M., Kokjohn, T., Emmerling, M., Weller, R., et al. (2000). Elevated A beta and apolipoprotein E in A beta PP transgenic mice and its relationship to amyloid accumulation in AD. Molecular Medicine, 6, 430-439.
21. Mayeux, R., Honig, L., Tang, M., Manly, J., Stern, Y., Schupf, N., et al. (2003). Plasma AßlO and Aß2 and AD: Relation to age, mortality, and risk. Neurology, 61, 1185-1190.
22. McKhann, G., Drachman, D., Folstein, M., et al. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Depart- ment of Health and Human Services Task Force on Alzheimer's disease. Neurology, 34, 939-944. (Pubitemid 14076461)
23. Mehta, P. D., Pirttila, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000). Plasma and cerebrospinal fluid levels of amyloid ß proteins 1-40 and 1-1-42 in Alzheimer's disease. Archives of Neurology, 57, 100-105. (Pubitemid 30027637)
24. Mehta, P., Pirttila, B., Patrick, B., et al. (2001). Amyloid ß protein 1-40 and 12 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer's disease. Neuroscience Letters, 304, 102-106. (Pubitemid 32377212)
25. Mehta, P., Mehta, S., Fedor, B., et al. (2003). Plasma amyloid beta protein 1-42 levels are increased in old Down Syndrome but not in young Down Syndrome. Neuroscience Letters, 342, 155-158. (Pubitemid 36570341)
26. Monsch, A., Bondi, M., Butters, N., Salmon, D., Katzman, R., & Thai, L. (1992). Compari- sons of verbal fluency tasks in the detection of dementia of the Alzheimer's type. Archives of Neurology, 49, 1253-1258.
27. Morris, J., Heyman, A., Mohs, R., Hughes, J., van Belle, G., Fillenbaum, G., et al. (1989).
28. The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology, 39, 1159-1165.
29. Petersen, R., Smith, G., Waring, S., Ivnik, R., Tangalos, E., & Kokmen, E. (1999). Mild cognitive impairment: Clinical characterization and outcome. Archives of Neurology, 56, 303-308. (Pubitemid 29120227)
30. Pomara, N., Willoughby, L., Sidtis, J., & Mehta, P. (2005). Selective reductions in plasma Aß 1-1-42 in healthy elderly subjects during longitudinal follow-up. American Journal of Geriatric Psychiatry, 13, 914-917. (Pubitemid 46638681)
31. Scheuner, D., Eckman, C, Jansen, M., et al. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Natural Medicine, 2, 864-870. Selkoe, D. J. (2001). Alzheimer's disease: Genes, proteins, and therapy. Physiological Reviews, 81, 741-766.
32. Skoog, L, Davidsson, P., Aevarsson, 0., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003). Cerebrospinal fluid Aßl-42 is reduced before onset of sporadic dementia: A population-based study in 85-year-olds. Dementia & Geriatric Cognitive Disorders, 15, 169-176.
33. Tammen, H., Schulte, L, Hess, R., Menzel, C, Kellmann, M., Mohring, T., & Schulz-Knappe, P. (2005). Peptidomic analysis of human blood specimens: Comparison between plasma specimens and serum by differential peptide display. Proteomics, 5(13), 3414-3422. (Pubitemid 41192047)
34. Van Oijen, M., Hofman, A., Soares, H., Koudstall, P., & Breteler, M. L. (2006). Plasma Aß 1-40 and Aß 1-1-42 and the risk of dementia: A prospective case-cohort study. Lancet Neurology, 5, 655-660. (Pubitemid 44062411)
35. Wenham, P., Hanson, T., & Ashby, J. (2001). Interference in spectrophotometric analysis of cerebrospinal fluid by haemolysis induced by transport through a pneumatic tube system. Annals of Clinical Biochemistry, 38, 371-375. (Pubitemid 32626080)
36. Whitehouse, P., Lerner, A., & Hederá, P. (1993). Dementia. In K. M. Heilman & E. Valenstein (Eds.), Clinical neuropsychology (3rd ed.). New York: Oxford Press.
37. Zlokavic, B. (2004). Clearing amyloid through the blood-brain barrier. Journal ofNeuro- chemistry, 89,807-811.